Abstracts tagged "inflammation and joint destruction"

Abstract Number: 2006 • 2019 ACR/ARP Annual Meeting
Pyruvate Kinase M2 May Contribute to the Inflammation and Joint Destruction in Rheumatoid Arthritis
Dong Woo Han ¹, Yong Seok Choi ¹, You-Jung Ha², Eun Hye Park ², Eun Ha Kang ², Yeong-Wook Song ³ and Yun Jong Lee ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Pyruvate kinase M2 (PKM2), one of glycolytic enzymes, is an emerging molecule that plays significant roles in tumor growth as well as inflammatory process.…
Abstract Number: 173 • 2016 ACR/ARHP Annual Meeting
S100A8/A9, a Potent Serum and Molecular Imaging Biomarker for Synovial Inflammation and Joint Destruction in Seronegative Experimental Arthritis
Edwin J. W. Geven¹, Martijn H. J. van den Bosch¹, Shahla Abdolahi-Roodsaz¹, Annet W. Sloetjes¹, Sven Hermann², Michael Schäfers², Marije I. Koenders¹, Dirk Föll³, Johannes Roth⁴, Thomas Vogl⁴ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²European Institute for Molecular Imaging, University of Münster, Münster, Germany, ³Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, ⁴Institute of Immunology, University of Münster, Münster, Germany
Background/Purpose: Seronegative joint diseases, including psoriatic arthritis and juvenile idiopathic arthritis, are characterized by the lack of autoantibodies, which are relevant biomarkers for predicting disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].